<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "12: discovering", fill: "#e8000d"},
{source: "12: discovering", target: "12: drugs since inception which", fill: "#e8000d"},
{source: "12: drugs since inception which", target: "12: will continue", fill: "#e8000d"},
{source: "12: will continue", target: "12: significant research", fill: "#e8000d"},
{source: "12: significant research", target: "12: development expenditures", fill: "#e8000d"},
{source: "12: discovering", target: "14: commercializing", fill: "#e52b50"},
{source: "14: commercializing", target: "14: BYETTA or SYMLIN ", fill: "#e52b50"},
{source: "14: BYETTA or SYMLIN ", target: "14: drug candidates", fill: "#e52b50"},
{source: "14: commercializing", target: "15: next few years as", fill: "#654321"},
{source: "15: next few years as", target: "15: commercial function", fill: "#654321"},
{source: "15: commercial function", target: "15: immediate future", fill: "#654321"},
{source: "15: immediate future", target: "15: BYETTA and SYMLIN ", fill: "#654321"},
{source: "15: BYETTA and SYMLIN ", target: "15: development", fill: "#654321"},
{source: "15: development", target: "15: activities", fill: "#654321"},
{source: "15: activities", target: "15: drug candidates", fill: "#654321"},
{source: "15: drug candidates", target: "15: development pipeline", fill: "#654321"},
{source: "15: next few years as", target: "20: generate product revenue", fill: "#922724"},
{source: "20: generate product revenue", target: "20: future will depend solely on", fill: "#922724"},
{source: "20: future will depend solely on", target: "20: commercialization", fill: "#922724"},
{source: "20: generate product revenue", target: "21: commercialization", fill: "#fffdd0"},
{source: "21: commercialization", target: "21: BYETTA and SYMLIN ", fill: "#fffdd0"},
{source: "21: BYETTA and SYMLIN ", target: "21: acceptance", fill: "#fffdd0"},
{source: "21: acceptance", target: "21: medical community", fill: "#fffdd0"},
{source: "21: medical community", target: "21: third party payors", fill: "#fffdd0"},
{source: "21: third party payors", target: "21: safety profile as demonstrated", fill: "#fffdd0"},
{source: "21: safety profile as demonstrated", target: "21: patient population", fill: "#fffdd0"},
{source: "21: patient population", target: "21: successfully building", fill: "#fffdd0"},
{source: "21: successfully building", target: "21: sustaining manufacturing capacity", fill: "#fffdd0"},
{source: "21: sustaining manufacturing capacity", target: "21: competitive landscape", fill: "#fffdd0"},
{source: "21: competitive landscape", target: "21: compete with", fill: "#fffdd0"},
{source: "21: compete with", target: "21: indications", fill: "#fffdd0"},
{source: "21: commercialization", target: "28: Manufacturing ", fill: "#00fa9a"},
{source: "28: Manufacturing ", target: "28: facilities", fill: "#00fa9a"},
{source: "28: facilities", target: "28: manufacture drug products", fill: "#00fa9a"},
{source: "28: manufacture drug products", target: "28: market whether", fill: "#00fa9a"},
{source: "28: market whether", target: "28: United States ", fill: "#00fa9a"},
{source: "28: United States ", target: "28: inspections by", fill: "#00fa9a"},
{source: "28: inspections by", target: "28: the FDAs ", fill: "#00fa9a"},
{source: "28: the FDAs ", target: "28: cGMP regulations", fill: "#00fa9a"},
{source: "28: Manufacturing ", target: "35: manufacturing", fill: "#0095b6"},
{source: "35: manufacturing", target: "35: sufficient quantities", fill: "#0095b6"},
{source: "35: sufficient quantities", target: "35: new andor approved drug", fill: "#0095b6"},
{source: "35: new andor approved drug", target: "35: candidates", fill: "#0095b6"},
{source: "35: candidates", target: "35: timeconsuming", fill: "#0095b6"},
{source: "35: timeconsuming", target: "35: complex process", fill: "#0095b6"},
{source: "35: manufacturing", target: "START_HERE", fill: "#0095b6"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Pharmaceuticals</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Economic</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Material Aid</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Policy</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Riot</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Promise policy support</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Natural disaster</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization_of_love">Commercialization of love</a></td>
      <td>The notion of commercialization of love, that is not to be confused with prostitution (the commercialization of sexual activity), involves the definitions of romantic love and consumerism.\n\n\n== Sociological development ==\nThe commercialization of love is the ongoing process of infiltration of commercial and economical stimuli in the daily life of lovers and the association of monetary and non-monetary symbols and commodities in the love relationships.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Cellulosic_ethanol">Cellulosic ethanol</a></td>
      <td>Cellulosic ethanol is ethanol (ethyl alcohol) produced from cellulose (the stringy fiber of a plant) rather than from the plant's seeds or fruit. It can be produced from grasses, wood, algae, or other plants.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_use_of_space">Commercial use of space</a></td>
      <td>Commercial use of space is the provision of goods or services of commercial value by using equipment sent into Earth orbit or outer space.  This phenomenon – aka Space Economy (or New Space Economy) – is accelerating cross-sector innovation processes combining the most advanced space and digital technologies to develop a broad portfolio of space-based services.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_software">Commercial software</a></td>
      <td>Commercial software, or seldom payware, is a computer software that is produced for sale or that serves commercial purposes. Commercial software can be proprietary software or free and open-source software.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Drug_discovery">Drug discovery</a></td>
      <td>In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which new candidate medications are discovered.Historically, drugs were discovered by identifying the active ingredient from traditional remedies or by serendipitous discovery, as with penicillin. More recently, chemical libraries of synthetic small molecules, natural products or extracts were screened in intact cells or whole organisms to identify substances that had a desirable therapeutic effect in a process known as classical pharmacology.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medication">Medication</a></td>
      <td>Meditation is a practice in which an individual uses a technique – such as mindfulness, or focusing the mind on a particular object, thought, or activity – to train attention and awareness, and achieve a mentally clear and emotionally calm and stable state.Meditation  is practiced in numerous religious traditions. The earliest records of meditation (dhyana) are found in the Upanishads of Hindu philosophy, and meditation plays a salient role in the contemplative repertoire of Buddhism and Hinduism.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Mirati_Therapeutics">Mirati Therapeutics</a></td>
      <td>Mirati Therapeutics is an American targeted oncology company that focuses on the development of cancer therapeutics.\n\n\n== History ==\nMirati Therapeutics works largely in KRAS-mutation inhibition, and developing treatments for tumors that contain it.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Drug_development">Drug development</a></td>
      <td>Drug development is the process of bringing a new pharmaceutical drug to the market once a lead compound has been identified through the process of drug discovery.  It includes preclinical research on microorganisms and animals, filing for regulatory status, such as via the United States Food and Drug Administration for an investigational new drug to initiate clinical trials on humans, and may include the step of obtaining regulatory approval with a new drug application to market the drug.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Drug_design">Drug design</a></td>
      <td>Drug design, often referred to as rational drug design or simply rational design, is the inventive process of finding new medications based on the knowledge of a biological target. The drug is most commonly an organic small molecule that activates or inhibits the function of a biomolecule such as a protein, which in turn results in a therapeutic benefit to the patient.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Drug_metabolism">Drug metabolism</a></td>
      <td>Drug metabolism is the metabolic breakdown of drugs by living organisms, usually through specialized enzymatic systems. More generally, xenobiotic metabolism (from the Greek xenos "stranger"  and biotic "related to living beings") is the set of metabolic pathways that modify the chemical structure of xenobiotics, which are compounds foreign to an organism's normal biochemistry, such as any drug or poison.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Drug_pipeline">Drug pipeline</a></td>
      <td>A drug pipeline is the set of drug candidates that an individual pharmaceutical company or the entire pharmaceutical industry collectively has under discovery or development at any given point in time.  The drug pipeline is also sometimes restricted to a particular drug class or extended to mean the process of discovering drugs (the research and development pipeline).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Santaris_Pharma">Santaris Pharma</a></td>
      <td>Santaris Pharma A/S was a biopharmaceutical company founded in 2003 in Copenhagen, Denmark. The company also had a branch in San Diego, California that opened in 2009.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Phases_of_clinical_research">Phases of clinical research</a></td>
      <td>The phases of clinical research are the stages in which scientists conduct experiments with a health intervention to obtain sufficient evidence for a process considered effective as a medical treatment. For drug development, the clinical phases start with testing for safety in a few human subjects, then expand to many study participants (potentially tens of thousands) to determine if the treatment is effective.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development_hell">Development hell</a></td>
      <td>Development hell, development purgatory, and development limbo are media and software industry jargon for a project, concept, or idea that remains in development for an especially long time, often moving between different crews, scripts, game engines, or studios before it progresses to production, if it ever does. Projects in development hell are usually not released until development has reached a satisfying state worthy of being released, ready for production.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Professional_development">Professional development</a></td>
      <td>Professional development is learning to earn or maintain professional credentials such as academic degrees to formal coursework, attending conferences, and informal learning opportunities situated in practice. It has been described as intensive and collaborative, ideally incorporating an evaluative stage.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Renewable_energy_commercialization">Renewable energy commercialization</a></td>
      <td>Renewable energy commercialization involves the deployment of three generations of renewable energy technologies dating back more than 100 years. First-generation technologies, which are already mature and economically competitive, include biomass, hydroelectricity, geothermal power and heat.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing_Consent">Manufacturing Consent</a></td>
      <td>Manufacturing Consent: The Political Economy of the Mass Media is a 1988 book by Edward S. Herman and Noam Chomsky. It argues that the mass communication media of the U.S. "are effective and powerful ideological institutions that carry out a system-supportive propaganda function, by reliance on market forces, internalized assumptions, and self-censorship, and without overt coercion", by means of the propaganda model of communication.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Automotive_industry">Automotive industry</a></td>
      <td>The automotive industry comprises a wide range of companies and organizations involved in the design, development, manufacturing, marketing, and selling of motor vehicles. It is one of the world's largest industries by revenue (from 16 % such as in France up to 40 % to countries like Slovakia).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Murata_Manufacturing">Murata Manufacturing</a></td>
      <td>Murata Manufacturing Co., Ltd. (株式会社村田製作所, Kabushiki-gaisha Murata Seisakusho) is a Japanese manufacturer of electronic components, based in Nagaokakyo, Kyoto.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Write-in_candidate">Write-in candidate</a></td>
      <td>A write-in candidate is a candidate whose name does not appear on the ballot but seeks election by asking voters to cast a vote for the candidate by physically writing in the person's name on the ballot. Depending on electoral law it may be possible to win an election by winning a sufficient number of such write-in votes, which count equally as if the person was formally listed on the ballot.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidates_Tournament">Candidates Tournament</a></td>
      <td>The Candidates Tournament (or in some periods Candidates Matches) is a chess tournament organized by FIDE, chess's international governing body, since 1950, as the final contest to determine the challenger for the World Chess Championship. The winner of the Candidates earns the right to a match for the World Championship against the incumbent World Champion.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidates_Tournament_2022">Candidates Tournament 2022</a></td>
      <td>The 2022 Candidates Tournament is an upcoming eight-player chess tournament, to decide the challenger for the World Chess Championship 2023. The tournament is scheduled to take place at the Palace of Santoña in Madrid, Spain from June 16 to July 5, 2022, with the World Championship to follow in early 2023.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/2022_Lebanese_general_election">2022 Lebanese general election</a></td>
      <td>General elections were held in Lebanon on 15 May 2022. The country has for several years been the subject of chronic political instability as well as a serious economic crisis aggravated by the 2020 explosions that hit the Port of Beirut and faced large-scale demonstrations against the political class.Hezbollah and their allies lost their parliamentary majority but still won the Parliament speaker election.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Officer_candidate">Officer candidate</a></td>
      <td>Officer candidate or officer aspirant (OA) is a rank in some militaries of the world that is an appointed position while a person is in training to become an officer.  More often than not, an officer candidate was a civilian who applied to join the military directly as an officer.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>AMYLIN PHARMACEUTICALS INC      Item 1A Risk Factors                   CAUTIONARY FACTORS THAT MAY AFFECT FUTURE RESULTS         Except for the historical information <font color="blue">contained herein</font> or <font color="blue">incorporated</font> by     reference, this annual report on Form 10-K and the information <font color="blue">incorporated</font>     by reference contains forward-looking statements that <font color="blue">involve risks</font> and     <font color="blue">uncertainties</font></td>
    </tr>
    <tr>
      <td>These statements include <font color="blue">projections about</font> our <font color="blue">accounting</font> and     finances, plans and <font color="blue">objectives</font> for the future, future operating and economic     performance  and  other statements regarding <font color="blue">future performance</font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font>statements are not <font color="blue">guarantees</font> of <font color="blue">future performance</font> or events</td>
    </tr>
    <tr>
      <td>Our actual     results <font color="blue">may differ materially from</font> those discussed here</td>
    </tr>
    <tr>
      <td>Factors that could     cause or contribute to <font color="blue">differences</font> in our actual results include those     discussed in the following section, as well as those discussed in Part II,     Item 7 entitled “Management’s Discussion and Analysis of Financial Condition     and Results of Operations” and elsewhere <font color="blue">throughout</font> this annual report on     Form 10-K and in any other <font color="blue">documents</font> <font color="blue">incorporated</font> by reference into this     report</td>
    </tr>
    <tr>
      <td>You should consider <font color="blue">carefully</font> the following risk factors, together     with all of the other information included or <font color="blue">incorporated</font> in this annual     report on Form 10-K Each of these risk factors, either alone or taken     together,  could  <font color="blue">adversely</font> affect our business, operating results and     <font color="blue">financial condition</font>, as well as <font color="blue">adversely</font> affect the value of an <font color="blue">investment</font>     in our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>There may be <font color="blue"><font color="blue">additional</font> risks</font> that we do not presently     know of or that we currently believe are <font color="blue">immaterial which could also impair</font>     our business and <font color="blue">financial position</font></td>
    </tr>
    <tr>
      <td>We have a history of operating losses, anticipate <font color="blue">future losses</font>, and may     <font color="blue">never <font color="blue">become profitable</font></font></td>
    </tr>
    <tr>
      <td>We have experienced <font color="blue">significant</font> operating losses since our inception in     1987, including losses of dlra206dtta8 million in 2005, dlra157dtta2 million in 2004 and     dlra122dtta8 million in 2003</td>
    </tr>
    <tr>
      <td><font color="blue">As of <font color="blue">December </font></font>31, 2005, we had an <font color="blue">accumulated</font>     deficit of <font color="blue">approximately</font> dlra1dtta0 billion</td>
    </tr>
    <tr>
      <td>The extent of our <font color="blue">future losses</font> and     the  timing of <font color="blue">potential profitability</font> are uncertain, and we may never     achieve <font color="blue">profitable <font color="blue">operations</font></font></td>
    </tr>
    <tr>
      <td>We have been engaged in <font color="blue">discovering</font> and     developing drugs since inception, which has required, and <font color="blue">will continue</font> to     require, <font color="blue">significant</font> research and <font color="blue"><font color="blue">development</font> expenditures</font></td>
    </tr>
    <tr>
      <td>We derived     <font color="blue">substantially</font> all of our <font color="blue">revenues prior</font> to 2005 from <font color="blue">development</font> funding,     fees and <font color="blue"><font color="blue">milestone payments</font> under <font color="blue">collaborative</font> <font color="blue">agreement</font>s</font> and <font color="blue">from interest</font>     income</td>
    </tr>
    <tr>
      <td>We may not succeed in <font color="blue">commercializing</font> BYETTA or SYMLIN, or any of     our other <font color="blue">drug <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>We may incur substantial operating losses for at     least the <font color="blue">next few years as</font> we continue to expand our <font color="blue">commercial function</font> in     the <font color="blue">immediate future</font> for <font color="blue">BYETTA and SYMLIN </font>and our research and <font color="blue">development</font>     <font color="blue">activities</font> for the other <font color="blue">drug <font color="blue">candidates</font></font> in our <font color="blue">development</font> pipeline</td>
    </tr>
    <tr>
      <td><font color="blue">These     </font>losses, among other things, have had and will have an adverse effect on our     <font color="blue">stockholders</font>’ equity and working capital</td>
    </tr>
    <tr>
      <td>Even if we <font color="blue">become profitable</font>, we     may not <font color="blue">remain profitable</font></td>
    </tr>
    <tr>
      <td>We began selling, marketing and <font color="blue">distributing</font> our <font color="blue">first products</font>, BYETTA and     SYMLIN, in 2005 and we will depend heavily on the success of those products     in the marketplace</td>
    </tr>
    <tr>
      <td>Prior to the launch <font color="blue">of BYETTA </font>and SYMLIN, we had never sold or marketed our     own products</td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">generate product revenue</font> in the foreseeable     <font color="blue">future will depend solely on</font> the <font color="blue">commercialization</font> of these products</td>
    </tr>
    <tr>
      <td>The     successful  <font color="blue">commercialization</font> of <font color="blue">BYETTA and SYMLIN </font><font color="blue">will depend on</font> many     factors, including the following:         •  <font color="blue">acceptance</font> of these first-in-class medicines by the <font color="blue">medical community</font>,     patients receiving therapy and <font color="blue"><font color="blue">third party</font> payors</font>;       •  a satisfactory efficacy and <font color="blue">safety profile as demonstrated</font> in a broad     <font color="blue">patient population</font>;       •  <font color="blue"><font color="blue">successfully</font> building</font> and <font color="blue">sustaining <font color="blue">manufacturing</font> capacity</font> to meet     demand;       •  the <font color="blue"><font color="blue">competitive</font> landscape</font> for approved and developing therapies that will     <font color="blue">compete with</font> the products; and       •   our  ability to expand the <font color="blue">indications</font> for which we can market the     products</td>
    </tr>
    <tr>
      <td>If we <font color="blue">encounter <font color="blue">safety issues</font> with</font> <font color="blue">BYETTA or SYMLIN </font>or any other drugs we     market or fail to <font color="blue">comply with</font> extensive <font color="blue">continuing <font color="blue">regulations</font> enforced by</font>     domestic  and  foreign  <font color="blue">regulatory</font>  <font color="blue">authorities</font>,  it could cause us to     <font color="blue">discontinue marketing</font> those drugs, reduce our revenues and harm our ability     to generate future revenues, which would negatively impact our financial     position</td>
    </tr>
    <tr>
      <td>BYETTA and SYMLIN, in addition to any other of our <font color="blue">drug <font color="blue">candidates</font></font> that may     be <font color="blue">approved by</font> the FDA, will be subject to <font color="blue"><font color="blue">continual review</font> by</font> the FDA, and     we <font color="blue">cannot assure</font> you that newly discovered or developed <font color="blue">safety issues</font> will     not arise</td>
    </tr>
    <tr>
      <td>With the use of any of our <font color="blue">marketed drugs by</font> a <font color="blue">wide patient</font>     population,  serious  adverse  <font color="blue">events may</font> occur from time to time that     initially  do not appear to relate to the drug itself, and only if the     <font color="blue">specific event</font> occurs with some <font color="blue">regularity over</font> a period of time does the     drug become suspect as having a <font color="blue">causal relationship</font> to the <font color="blue">adverse event</font></td>
    </tr>
    <tr>
      <td>Any  <font color="blue"><font color="blue">safety issues</font> could</font> cause us to suspend or <font color="blue">cease marketing</font> of our     <font color="blue">approved products</font>, subject us to substantial <font color="blue">liabilities</font>, and <font color="blue">adversely</font>     affect our revenues and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>Moreover,  the  marketing  of our <font color="blue">approved products</font> will be subject to     extensive  <font color="blue">regulatory</font>  <font color="blue">requirements</font>  <font color="blue">administered</font> by the FDA and other     <font color="blue">regulatory</font> bodies, including <font color="blue">adverse event</font> reporting <font color="blue">requirements</font> and the     FDA’s <font color="blue">general prohibition against promoting products</font> for <font color="blue">unapproved uses</font></td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">manufacturing</font> <font color="blue">facilities</font></font> for our <font color="blue">approved products</font> are also subject to     <font color="blue">continual review</font> and periodic                                           18     ______________________________________________________________________                                                  inspection  and approval of <font color="blue"><font color="blue">manufacturing</font> modifications</font></td>
    </tr>
    <tr>
      <td><font color="blue">Manufacturing     </font><font color="blue">facilities</font> that <font color="blue"><font color="blue">manufacture</font> <font color="blue"><font color="blue">drug product</font>s</font></font> for the US market, whether they     are located inside or outside <font color="blue">the <font color="blue">United States</font></font>, are subject to biennial     <font color="blue">inspections by</font> the FDA and must <font color="blue">comply with</font> the FDA’s <font color="blue">cGMP <font color="blue">regulations</font></font></td>
    </tr>
    <tr>
      <td>The     FDA stringently applies <font color="blue">regulatory</font> standards for <font color="blue">manufacturing</font></td>
    </tr>
    <tr>
      <td>Failure to     <font color="blue">comply with</font> any of these post-approval <font color="blue">requirements</font> can, among other things,     result in warning letters, product seizures, recalls, fines, injunctions,     <font color="blue">suspensions</font> or <font color="blue">revocations</font> of <font color="blue">marketing licenses</font>, operating <font color="blue">restrictions</font> and     <font color="blue">criminal prosecutions</font></td>
    </tr>
    <tr>
      <td>Any of these <font color="blue">enforcement</font> actions, any <font color="blue">unanticipated</font>     changes  in  existing  <font color="blue">regulatory</font>  <font color="blue">requirements</font> or the adoption of new     <font color="blue">requirements</font>, or any <font color="blue">safety issues</font> that arise with any <font color="blue">approved products</font>,     could <font color="blue">adversely</font> affect our ability to <font color="blue">market products</font> and <font color="blue">generate revenues</font>     and thus <font color="blue">adversely</font> affect our ability to continue our business</td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">manufacture</font>rs</font> of our products and <font color="blue">drug <font color="blue">candidates</font></font> also are subject to     <font color="blue">numerous federal</font>, state, local and <font color="blue">foreign laws</font> relating to <font color="blue">such matters as</font>     safe working <font color="blue">conditions</font>, <font color="blue">manufacturing</font> practices, environmental protection,     <font color="blue">fire hazard control</font> and <font color="blue">hazardous</font> substance disposal</td>
    </tr>
    <tr>
      <td>In the future, our     <font color="blue"><font color="blue">manufacture</font>rs</font> may incur <font color="blue">significant</font> costs to <font color="blue">comply with</font> those laws and     <font color="blue">regulations</font>, which could increase our <font color="blue">manufacturing</font> costs and reduce our     ability to operate profitably</td>
    </tr>
    <tr>
      <td>We do not <font color="blue">manufacture</font> our own <font color="blue"><font color="blue">drug product</font>s</font> or <font color="blue">drug <font color="blue">candidates</font></font> and may not     be able to obtain adequate supplies, which could cause delays, subject us to     <font color="blue">product shortages</font>, or <font color="blue">reduce product sales</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">manufacturing</font> of <font color="blue">sufficient quantities</font> of new and/or approved drug     <font color="blue">candidates</font> is a time-consuming and <font color="blue">complex process</font></td>
    </tr>
    <tr>
      <td>We currently have no     <font color="blue">manufacturing</font> capabilities</td>
    </tr>
    <tr>
      <td>In order to <font color="blue"><font color="blue">successfully</font> <font color="blue">commercialize</font></font> our     products, including BYETTA and SYMLIN, and continue to develop our drug     <font color="blue">candidates</font>,  including exenatide LAR, we need to contract or otherwise     arrange for the <font color="blue">necessary</font> <font color="blue">manufacturing</font></td>
    </tr>
    <tr>
      <td>There are a limited number of <font color="blue"><font color="blue">manufacture</font>rs</font> that operate under the FDA’s     <font color="blue">cGMP <font color="blue">regulations</font></font> capable of <font color="blue">manufacturing</font> for us</td>
    </tr>
    <tr>
      <td>If we are not able to     arrange  for  and  maintain  third-party <font color="blue">manufacturing</font> on <font color="blue">commercially</font>     <font color="blue">reasonable terms</font>, or we lose one of our <font color="blue">sole source suppliers used</font> for our     <font color="blue">existing products</font> or for some <font color="blue">components</font> of our <font color="blue">manufacturing</font> processes for     our products or <font color="blue">drug <font color="blue">candidates</font></font>, we may not be able to market our products     or complete <font color="blue">development</font> of our <font color="blue">drug <font color="blue">candidates</font></font> on a <font color="blue">timely basis</font>, if at all</td>
    </tr>
    <tr>
      <td>Reliance on third-party <font color="blue"><font color="blue">manufacture</font>rs</font> limits our control regarding certain     aspects of the <font color="blue">manufacturing</font> process and <font color="blue">therefore <font color="blue">exposes us</font></font> to a variety     of <font color="blue">significant</font> risks, including, but not limited to, risks to our ability to     <font color="blue">commercialize</font> our products or conduct <font color="blue">clinical trials</font>, risks of <font color="blue">reliance on</font>     the third-party for <font color="blue">regulatory</font> compliance and quality assurance, third-party     refusal to supply on a long-term basis, the <font color="blue">possibility</font> of breach of the     <font color="blue">manufacturing</font>  <font color="blue">agreement</font>  by  the  third-party  and the <font color="blue">possibility</font> of     <font color="blue">termination</font> or non-renewal of the <font color="blue">agreement</font> by the third-party, based on its     business priorities, at a time that is costly or <font color="blue">inconvenient</font> for us</td>
    </tr>
    <tr>
      <td>If any of our existing or future <font color="blue"><font color="blue">manufacture</font>rs</font> cease to <font color="blue">manufacture</font> or are     otherwise  unable to timely deliver <font color="blue">sufficient quantities</font> <font color="blue">of BYETTA </font>or     SYMLIN, our ability to <font color="blue"><font color="blue">successfully</font> <font color="blue">commercialize</font></font> our <font color="blue">products will</font> be     diminished</td>
    </tr>
    <tr>
      <td>Likewise, if any of our existing or future <font color="blue"><font color="blue">manufacture</font>rs</font> cease     to  <font color="blue">manufacture</font>  or  are otherwise unable to timely deliver sufficient     quantities of BYETTA, SYMLIN, exenatide LAR or our other <font color="blue">drug <font color="blue">candidates</font></font>, in     either bulk or dosage form, or other product <font color="blue">components</font>, including pens for     the  delivery  of  these  products,  we  may need to engage <font color="blue">additional</font>     <font color="blue"><font color="blue">manufacture</font>rs</font>, so that we will be able to continue our <font color="blue">commercialization</font> and     <font color="blue">development</font> efforts for these products or <font color="blue">drug <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>The cost and time     to establish these new <font color="blue"><font color="blue">manufacturing</font> <font color="blue">facilities</font></font> would be substantial</td>
    </tr>
    <tr>
      <td>As a     result, using a new <font color="blue">manufacture</font>r could disrupt our ability to market our     products, subject us to <font color="blue">product shortages</font>, <font color="blue">reduce product sales</font>, and/or     reduce our <font color="blue">profit margins</font></td>
    </tr>
    <tr>
      <td>Any delay or <font color="blue">disruption</font> in the <font color="blue">manufacturing</font> of     <font color="blue">bulk product</font>, the dosage form of our products or other product <font color="blue">components</font>,     including pens for delivery of our products, could also harm our reputation     in the medical and <font color="blue">patient communities</font></td>
    </tr>
    <tr>
      <td>We   have   entered   into   <font color="blue">agreement</font>s  with  Bachem  California  and     Mallinckrodt, Inc</td>
    </tr>
    <tr>
      <td>for the long-term supply of <font color="blue">bulk exenatide</font></td>
    </tr>
    <tr>
      <td>We have     long-term  <font color="blue">agreement</font>s  with  CP  Pharmaceuticals Ltd, a subsidiary of     Wockhardt Ltd, and Baxter <font color="blue">Pharmaceutical </font>Solutions LLC, a subsidiary of     Baxter, Inc,  for the dosage form <font color="blue">of BYETTA </font>in <font color="blue">cartridges</font></td>
    </tr>
    <tr>
      <td>Currently,     Baxter’s  <font color="blue">manufacturing</font>  process  for  BYETTA <font color="blue">cartridges</font> is undergoing     <font color="blue">validation</font></td>
    </tr>
    <tr>
      <td>We have an <font color="blue">agreement</font> with Lilly to supply pens for delivery of     BYETTA in <font color="blue">cartridges</font></td>
    </tr>
    <tr>
      <td>We have long-term <font color="blue">agreement</font>s with <font color="blue">Bachem and Lonza </font>for     the  commercial  <font color="blue">manufacture</font>  of  bulk pramlintide acetate, the active     ingredient contained <font color="blue">in SYMLIN </font>and used in our treatment of obesity with     pramlintide <font color="blue">development</font> program</td>
    </tr>
    <tr>
      <td>We have a long-term contract with <font color="blue">Baxter     </font>for the dosage form of SYMLIN in vials</td>
    </tr>
    <tr>
      <td>We have a long-term <font color="blue">agreement</font> with     <font color="blue">CP Pharmaceuticals </font>for the dosage form of SYMLIN in <font color="blue">cartridges</font> and are     working with a <font color="blue">manufacture</font>r, Ypsomed AG, for the <font color="blue">manufacture</font> of disposable     pens  for delivery of SYMLIN in <font color="blue">cartridges</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">manufacture</font>rs</font> have not     produced <font color="blue">BYETTA or SYMLIN </font>for commercial use for a <font color="blue">sustained period</font> of time</td>
    </tr>
    <tr>
      <td>As such, <font color="blue">additional</font> unforeseeable risks may be <font color="blue">encountered as</font> we, together     with our <font color="blue"><font color="blue">manufacture</font>rs</font>, continue to develop <font color="blue">familiarity</font> and experience with     regard  to  <font color="blue">manufacturing</font>  our products</td>
    </tr>
    <tr>
      <td>Furthermore, we and the other     <font color="blue"><font color="blue">manufacture</font>rs</font>  used for our <font color="blue">drug <font color="blue">candidates</font></font> may not be able to produce     supplies in <font color="blue">commercial quantities</font> if our <font color="blue">drug <font color="blue">candidates</font></font> are approved</td>
    </tr>
    <tr>
      <td><font color="blue">While     </font>we believe that business <font color="blue">relations between us</font> and our <font color="blue"><font color="blue">manufacture</font>rs</font> are     <font color="blue">generally</font> good, we <font color="blue">cannot <font color="blue">predict whether</font></font> any of the <font color="blue"><font color="blue">manufacture</font>rs</font> that we     <font color="blue">may use will meet</font> our <font color="blue">requirements</font> for quality, quantity or <font color="blue">timeliness</font> for     the <font color="blue">manufacture</font> of <font color="blue">bulk exenatide</font> or pramlintide acetate, dosage form of     BYETTA or SYMLIN, or pens</td>
    </tr>
    <tr>
      <td>Therefore, we may not be able to obtain supplies     of <font color="blue">products with</font>                                           19     ______________________________________________________________________                                                  acceptable quality, on acceptable terms or in <font color="blue">sufficient quantities</font>, if at     all</td>
    </tr>
    <tr>
      <td>Our <font color="blue">dependence on <font color="blue">third parties</font></font> for the <font color="blue">manufacture</font> of <font color="blue">products may</font>     also reduce our gross <font color="blue">profit margins</font> and our ability to develop and deliver     products in a <font color="blue">timely manner</font></td>
    </tr>
    <tr>
      <td>In order to <font color="blue">manufacture</font> on a <font color="blue">commercial scale</font> the once-weekly <font color="blue">formulation</font> of     exenatide LAR, if it is <font color="blue">approved by</font> the FDA, we must design, construct,     validate and license a <font color="blue">new <font color="blue">facility</font></font></td>
    </tr>
    <tr>
      <td>We <font color="blue">will depend upon</font> <font color="blue">Alkermes </font>and     Parsons to <font color="blue">assist us</font> in the design, construction and <font color="blue">validation</font> of the     <font color="blue">manufacturing</font>  <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>We  have  never  established  or  operated a     <font color="blue">manufacturing</font>  <font color="blue">facility</font>  and <font color="blue">cannot assure</font> you that we will be able to     <font color="blue"><font color="blue">successfully</font> establish</font> or operate such a <font color="blue">facility</font> in a timely or economical     manner,  or  at  all</td>
    </tr>
    <tr>
      <td>In  addition,  we <font color="blue">will depend upon</font> <font color="blue">Alkermes </font>to     <font color="blue">successfully</font> develop and transfer to us its <font color="blue">technology</font> for <font color="blue">manufacturing</font> the     once-weekly <font color="blue">formulation</font> of exenatide LAR  While <font color="blue">Alkermes </font>has <font color="blue">manufacture</font>d     exenatide LAR in small quantities for use in <font color="blue">clinical trials</font>, we cannot     assure you that a <font color="blue">commercial scale</font> <font color="blue">manufacturing</font> process for exenatide LAR     will be <font color="blue">successfully</font> developed and/or transferred to us in a timely or     <font color="blue">economical manner</font>, or at all</td>
    </tr>
    <tr>
      <td>In addition, we are <font color="blue"><font color="blue">dependent</font> upon</font> <font color="blue">Alkermes </font>to     supply us with <font color="blue">commercial quantities</font> of the polymer required to <font color="blue">manufacture</font>     exenatide LAR We also will need to obtain <font color="blue">sufficient supplies</font> of diluent     <font color="blue">necessary</font> for commercial <font color="blue">manufacture</font> of exenatide LAR If we, <font color="blue">together with</font>     Alkermes,  are  unable  to  <font color="blue">successfully</font>  develop  a  <font color="blue">commercial scale</font>     <font color="blue">manufacturing</font> process and increase our <font color="blue">manufacturing</font> scale to a <font color="blue">commercially</font>     <font color="blue">viable level</font>, we may not be able to <font color="blue">commercially</font> launch exenatide <font color="blue">LAR         </font>Our ability to <font color="blue">generate revenues</font> will be diminished if we fail to obtain     acceptable prices or an <font color="blue">adequate level</font> of <font color="blue">reimbursement</font> for our products     from third-party payors</td>
    </tr>
    <tr>
      <td>The <font color="blue">requirements</font> governing product licensing, pricing and <font color="blue">reimbursement</font> vary     <font color="blue">widely from country</font> to country</td>
    </tr>
    <tr>
      <td>In many countries, the pricing     <font color="blue">review period begins</font> after <font color="blue">product licensing approval</font> is granted</td>
    </tr>
    <tr>
      <td>As a     result, we may obtain <font color="blue">regulatory</font> approval for a product in a particular     country, but then be subject to price <font color="blue">regulations</font> that reduce our revenues     from the sale of the product</td>
    </tr>
    <tr>
      <td>Also, in some foreign markets, pricing of     <font color="blue">prescription</font> <font color="blue">pharmaceuticals</font> is subject to continuing <font color="blue"><font color="blue">government</font>al</font> control     even after initial marketing approval</td>
    </tr>
    <tr>
      <td>With respect to BYETTA, SYMLIN, or     any of our potential <font color="blue">drug <font color="blue">candidates</font></font>, we cannot be certain that the products     will be considered <font color="blue">cost <font color="blue">effective</font></font> and that <font color="blue">reimbursement</font> will be available     or will be sufficient to allow us to sell the <font color="blue">products on</font> a <font color="blue">competitive</font>     basis</td>
    </tr>
    <tr>
      <td>The <font color="blue">continuing efforts</font> of <font color="blue">government</font>, private health insurers, and other     third-party payors to contain or reduce the costs of <font color="blue">health care through</font>     various means, including efforts to increase the amount of patient co-pay     obligations, may limit our <font color="blue">commercial opportunity</font></td>
    </tr>
    <tr>
      <td>In <font color="blue">the <font color="blue">United States</font></font>, we     expect  that  there  <font color="blue">will continue</font> to be a number of federal and state     proposals to implement <font color="blue"><font color="blue">government</font> control over</font> the pricing of <font color="blue">prescription</font>     <font color="blue">pharmaceuticals</font></td>
    </tr>
    <tr>
      <td>In addition, increasing emphasis on managed care in the     <font color="blue"><font color="blue">United States</font> </font><font color="blue">will continue</font> to <font color="blue">put pressure on</font> the rate of adoption and     pricing of <font color="blue">pharmaceutical products</font></td>
    </tr>
    <tr>
      <td><font color="blue">Significant </font><font color="blue">uncertainty</font> exists as to the <font color="blue">reimbursement</font> status of newly     <font color="blue">approved health care products such as</font> <font color="blue">BYETTA and SYMLIN </font>Third-party payors,     including Medicare, are <font color="blue">challenging</font> the <font color="blue">prices charged</font> for <font color="blue">medical products</font>     and services</td>
    </tr>
    <tr>
      <td><font color="blue">Government </font>and other third-party payors increasingly are     attempting to <font color="blue">contain health care costs by limiting both coverage</font> and the     level of <font color="blue">reimbursement</font> for new drugs and by refusing, in some cases, to     <font color="blue">provide coverage</font> for uses of <font color="blue">approved products</font> for disease <font color="blue">indications</font> for     which the FDA has not <font color="blue">granted labeling approval</font></td>
    </tr>
    <tr>
      <td>Third-party insurance     <font color="blue">coverage may</font> not be available to patients for BYETTA and/or SYMLIN or any     other products we discover and develop</td>
    </tr>
    <tr>
      <td>If <font color="blue">government</font> and other third-party     payors do not <font color="blue">provide adequate coverage</font> and <font color="blue">reimbursement</font> levels for our     products, the market <font color="blue">acceptance</font> of these <font color="blue">products may</font> be reduced</td>
    </tr>
    <tr>
      <td>We may require <font color="blue">future capital</font> and are uncertain of the <font color="blue">availability</font> or terms     of <font color="blue">additional</font> funding, and if <font color="blue">additional</font> capital is not available or not     available  on  acceptable terms, we may have to reduce the size of our     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We may need to continue to find <font color="blue">additional</font> sources of capital in order to     <font color="blue"><font color="blue">successfully</font> <font color="blue">commercialize</font></font> <font color="blue">BYETTA and SYMLIN </font>and to complete the <font color="blue">development</font>     and  <font color="blue">commercialization</font>  of  our  drug  <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">future capital</font>     <font color="blue">requirements</font> <font color="blue">will depend on</font> many factors, including:         •  the costs of marketing and selling BYETTA and SYMLIN;       •  our ability, and the ability of any partner, to <font color="blue">effective</font>ly market, sell     and distribute BYETTA and SYMLIN;       •  the costs of <font color="blue">manufacturing</font> BYETTA, SYMLIN, exenatide LAR, and our other     <font color="blue">drug <font color="blue">candidates</font></font>;       •  the time and <font color="blue">costs involved</font> in designing, <font color="blue">constructing</font>, validating and     licensing a <font color="blue">facility</font> to <font color="blue">manufacture</font> exenatide LAR;       •    the   <font color="blue">continuation</font>  of  our  <font color="blue">collaboration</font>  with  Lilly  for  the     <font color="blue">commercialization</font> <font color="blue">of BYETTA </font>and the further <font color="blue">development</font> of sustained-release     <font color="blue">formulation</font>s of BYETTA, including exenatide LAR;       •  our ability to meet milestone <font color="blue">objectives</font> under our <font color="blue">collaboration</font> with     Lilly;       •  our access to <font color="blue">loan amounts under</font> our <font color="blue">collaboration</font> with Lilly;       •  progress with our <font color="blue">pre<font color="blue">clinical studies</font></font> and <font color="blue">clinical trials</font>;       •  the time and <font color="blue">costs involved</font> in obtaining <font color="blue">regulatory</font> approvals for the     marketing of any of our <font color="blue">drug <font color="blue">candidates</font></font>;       •  scientific progress in our other <font color="blue">research programs</font> and the magnitude of     these programs;       •  our ability to <font color="blue">establish one</font> or more <font color="blue">development</font> or <font color="blue">commercialization</font>     <font color="blue">arrangements</font> for our <font color="blue">drug <font color="blue">candidates</font></font>;                                           20     ______________________________________________________________________                                                  •   the  <font color="blue">acquisition</font> and <font color="blue">implementation cost</font> of any potential realized     licenses or <font color="blue">acquisition</font>s;       •   the <font color="blue">costs involved</font> in preparing, filing, prosecuting, maintaining and     <font color="blue">enforcing patents</font> or <font color="blue">defending ourselves against competing technological</font> and     market <font color="blue">development</font>s; and       •   the potential need to <font color="blue"><font color="blue">repay existing</font> <font color="blue">indebtedness</font></font></td>
    </tr>
    <tr>
      <td>You should be aware that:         •   we may not be able to obtain <font color="blue">additional</font> <font color="blue">financial resources</font> in the     <font color="blue">necessary</font> time frame or on terms favorable to us, if at all;       •  any available <font color="blue">additional</font> financing may not be adequate; and       •  we may be required to use a portion of <font color="blue">future financing</font> to <font color="blue">repay existing</font>     <font color="blue">indebtedness</font> to our current or <font color="blue">future creditors</font></td>
    </tr>
    <tr>
      <td>In the event we are unable to obtain <font color="blue">additional</font> financing on acceptable     terms, we may have to delay, scale back or <font color="blue">eliminate one</font> or more of our     <font color="blue">development</font> or <font color="blue">commercialization</font> programs, or obtain funds by entering into     more <font color="blue">arrangements</font> with <font color="blue">collaborative</font> partners or others that may require us     to <font color="blue">relinquish</font> rights to certain of our <font color="blue">drug <font color="blue">candidates</font></font> or <font color="blue">technologies</font> that     we would not otherwise <font color="blue">relinquish</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>in the bio<font color="blue">technology</font> and <font color="blue">pharmaceutical industries may</font> result in     <font color="blue">competing products</font>, superior marketing of other products and <font color="blue">lower revenues</font>     or profits for us</td>
    </tr>
    <tr>
      <td>There are many companies that are seeking to develop products and therapies     for the treatment of diabetes and other <font color="blue">metabolic disorders</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">competitors</font>     include <font color="blue">multinational pharmaceutical</font> and chemical companies, specialized     bio<font color="blue">technology</font> firms and <font color="blue">universities</font> and other <font color="blue">research institutions</font></td>
    </tr>
    <tr>
      <td>A     number of our largest <font color="blue">competitors</font>, including AstraZeneca, Bristol-Myers     Squibb, Sanofi-Aventis, Lilly, GlaxoSmithKline, Merck &amp; Co, Novartis, Novo     Nordisk, Pfizer and Takeda Pharmaceuticals, are pursuing the <font color="blue">development</font> or     marketing of <font color="blue">pharmaceuticals</font> that target the <font color="blue">same diseases</font> that we are     targeting,  and it is possible that the number of <font color="blue">companies seeking</font> to     develop products and therapies for the treatment of diabetes, obesity,     <font color="blue">cardiovascular disease</font> and other <font color="blue">metabolic disorders</font> will increase</td>
    </tr>
    <tr>
      <td>Many of     our <font color="blue">competitors</font> have <font color="blue">substantially</font> greater financial, technical, human and     other  resources  than  we  do  and may be better equipped to develop,     <font color="blue">manufacture</font> and market <font color="blue">technologically</font> superior products</td>
    </tr>
    <tr>
      <td>In addition, many     of these <font color="blue">competitors</font> have <font color="blue">significant</font>ly greater experience than we do in     undertaking  preclinical  testing  and  human  <font color="blue">clinical studies</font> of new     <font color="blue">pharmaceutical products</font> and in obtaining <font color="blue">regulatory</font> approvals of human     <font color="blue">therapeutic products</font></td>
    </tr>
    <tr>
      <td>Accordingly, our <font color="blue">competitors</font> may succeed in obtaining     FDA approval for superior products</td>
    </tr>
    <tr>
      <td>Furthermore, now that we have received     FDA approval for BYETTA and SYMLIN, we may also be <font color="blue">competing against</font> other     companies  with  respect to our <font color="blue">manufacturing</font> and <font color="blue">product <font color="blue">distribution</font></font>     <font color="blue">efficiency</font> and sales and marketing capabilities, areas in which we have     limited or no experience as an <font color="blue">organization</font></td>
    </tr>
    <tr>
      <td>Our initial target <font color="blue">patient population</font> for BYETTA is people <font color="blue">with diabetes</font> who     have not achieved <font color="blue">adequate glycemic control using metformin</font>, a <font color="blue">sulfonylurea</font>     or <font color="blue">both two common oral therapies</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">target population</font> for SYMLIN is     people with either type 2 or type 1 diabetes whose therapy includes multiple     mealtime  insulin  <font color="blue">injections</font>  daily</td>
    </tr>
    <tr>
      <td>Other products are currently in     <font color="blue">development</font>  or exist in the market that <font color="blue">may compete directly with</font> the     products that we are developing or marketing</td>
    </tr>
    <tr>
      <td>Various other products are     available or in <font color="blue">development</font> to treat type 2 diabetes, including:         •  <font color="blue">sulfonylurea</font>s;       •  metformin;       •  insulins, including injectable and <font color="blue">inhaled versions</font>;       •  glinides;       •  PPARS;       •  DPP-IV <font color="blue">inhibitors</font>;       •  alpha-glucosidase <font color="blue">inhibitors</font>; and       •  <font color="blue">thiazolidinediones</font> (TZDs)</td>
    </tr>
    <tr>
      <td>In addition, several companies are developing <font color="blue">various approaches</font> to improve     <font color="blue">treatments</font> for type 1 and type 2 diabetes</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot <font color="blue">predict whether</font></font> our     <font color="blue">products will</font> have <font color="blue">sufficient advantages</font> to cause <font color="blue">health care professionals</font>     to  adopt  them over other products or that our <font color="blue">products will</font> offer an     <font color="blue">economically feasible alternative</font> to other products</td>
    </tr>
    <tr>
      <td>Our products could     <font color="blue">become obsolete</font> before we <font color="blue">recover expenses incurred</font> in developing these     products</td>
    </tr>
    <tr>
      <td>We are subject to “fraud and abuse” and similar laws and <font color="blue">regulations</font>, and a     failure to <font color="blue">comply with</font> such <font color="blue">regulations</font> or prevail in any <font color="blue">litigation</font> related     to <font color="blue">noncompliance could harm</font> our business</td>
    </tr>
    <tr>
      <td>Upon approval of <font color="blue">BYETTA and SYMLIN </font>by the FDA, we became subject to various     health care “fraud and abuse” laws, such as the Federal False Claims Act,     the federal anti-kickback statute and other state and <font color="blue">federal laws</font> and     <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Pharmaceutical </font>companies have <font color="blue">faced lawsuits</font> and <font color="blue">investigations</font>     pertaining to violations of these laws and <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>We cannot                                           21     ______________________________________________________________________                                                  guarantee that measures that we have taken to <font color="blue">prevent such violations</font>,     including our corporate compliance program, will protect us from future     violations, lawsuits or <font color="blue">investigations</font></td>
    </tr>
    <tr>
      <td>If any such actions are instituted     against us, and we are not successful in defending ourselves or asserting     our rights, those actions could have a <font color="blue">significant</font> impact on our business,     including the imposition of <font color="blue">significant</font> fines or other sanctions</td>
    </tr>
    <tr>
      <td>We are <font color="blue">substantially</font> <font color="blue">dependent</font> on our <font color="blue">collaboration</font> with Lilly for the     <font color="blue">development</font> and <font color="blue">commercialization</font> <font color="blue">of BYETTA </font>and <font color="blue">dependent</font> on Lilly and     <font color="blue">Alkermes </font>for the <font color="blue">development</font> of exenatide <font color="blue">LAR         </font>We have <font color="blue">entered into</font> <font color="blue">collaborative</font> <font color="blue">arrangements</font> with Lilly, who currently     markets  diabetes therapies and is developing <font color="blue">additional</font> diabetes drug     <font color="blue">candidates</font>, to <font color="blue">commercialize</font> BYETTA and further develop sustained-release     <font color="blue">formulation</font>s  of BYETTA, including exenatide LAR We <font color="blue">entered into</font> this     <font color="blue">collaboration</font> in order to:         •  fund some of our research and <font color="blue">development</font> <font color="blue">activities</font>;       •  <font color="blue">assist us</font> in seeking and obtaining <font color="blue">regulatory</font> approvals; and       •  <font color="blue">assist us</font> in the successful <font color="blue">commercialization</font> <font color="blue">of BYETTA </font>and exenatide     <font color="blue">LAR         </font>In general, we <font color="blue">cannot control</font> the amount and timing of resources that <font color="blue">Lilly     </font>may devote to our <font color="blue">collaboration</font></td>
    </tr>
    <tr>
      <td>If Lilly fails to assist in the further     <font color="blue">development</font> of exenatide LAR or the <font color="blue">commercialization</font> of BYETTA, or if     Lilly’s efforts are not <font color="blue">effective</font>, our business may be <font color="blue">negatively affected</font></td>
    </tr>
    <tr>
      <td>We are <font color="blue">primarily relying on</font> Lilly to obtain <font color="blue">regulatory</font> approvals outside the     <font color="blue"><font color="blue">United States</font> </font>for BYETTA and exenatide LAR Our <font color="blue">collaboration</font> with Lilly may     not continue or result in <font color="blue"><font color="blue">successfully</font> <font color="blue">commercialize</font></font>d drugs</td>
    </tr>
    <tr>
      <td>Lilly can     terminate our <font color="blue">collaboration</font> at any time upon 60 days notice</td>
    </tr>
    <tr>
      <td>If Lilly ceased     funding and/or developing and <font color="blue">commercializing</font> BYETTA or sustained-release     <font color="blue">formulation</font>s of BYETTA, we would have to seek <font color="blue">additional</font> sources for funding     and may have to delay, reduce or <font color="blue">eliminate one</font> or more of our <font color="blue">development</font>     programs for these compounds</td>
    </tr>
    <tr>
      <td>We are also <font color="blue">dependent</font> on <font color="blue">Alkermes </font>for the     <font color="blue">development</font> of exenatide LAR If Alkermes’ <font color="blue">technology</font> is not <font color="blue">successfully</font>     developed  to  <font color="blue">effective</font>ly  deliver  exenatide  in a <font color="blue">sustained release</font>     <font color="blue">formulation</font>,  or  <font color="blue">Alkermes </font>does not <font color="blue">devote <font color="blue">sufficient resources</font></font> to the     <font color="blue">collaboration</font>, our efforts to develop <font color="blue">sustained release</font> <font color="blue">formulation</font>s of     <font color="blue">exenatide could</font> be delayed or curtailed</td>
    </tr>
    <tr>
      <td>If our patents are determined to be unenforceable or if we are unable to     obtain  <font color="blue">new patents based on current <font color="blue">patent <font color="blue"><font color="blue">application</font>s</font></font></font> or for future     <font color="blue">inventions</font>, we may not be able to <font color="blue">prevent others from using</font> our <font color="blue">intellectual</font>     property</td>
    </tr>
    <tr>
      <td>We own or hold <font color="blue">exclusive rights</font> to many issued US patents and pending US     <font color="blue">patent <font color="blue"><font color="blue">application</font>s</font></font> related to the <font color="blue">development</font> and <font color="blue">commercialization</font> of     exenatide, including BYETTA and exenatide LAR, SYMLIN and our other drug     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>These patents and <font color="blue"><font color="blue">application</font>s</font> cover composition-of-matter,     medical  <font color="blue">indications</font>, methods of use, <font color="blue">formulation</font>s and other inventive     results</td>
    </tr>
    <tr>
      <td>We do have issued and pending <font color="blue"><font color="blue">application</font>s</font> for <font color="blue">formulation</font>s <font color="blue">of BYETTA </font>and     exenatide LAR We also own or hold <font color="blue">exclusive rights</font> to <font color="blue">various foreign</font>     <font color="blue">patent <font color="blue"><font color="blue">application</font>s</font></font> that correspond to issued US patents or pending US     <font color="blue">patent <font color="blue"><font color="blue">application</font>s</font></font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">success will depend</font> in part on our ability to obtain <font color="blue">patent protection</font>     for our products and <font color="blue">drug <font color="blue">candidates</font></font> and <font color="blue">technologies</font> both in the United     States and other countries</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot guarantee</font> that any <font color="blue">patents will issue</font>     from any pending or future <font color="blue">patent <font color="blue"><font color="blue">application</font>s</font></font> owned by or licensed to us</td>
    </tr>
    <tr>
      <td>Alternatively, a <font color="blue">third party</font> may <font color="blue">successfully</font> <font color="blue">circumvent</font> our patents</td>
    </tr>
    <tr>
      <td>Our     rights  under  any  issued  <font color="blue">patents may</font> not <font color="blue">provide us with sufficient</font>     protection against <font color="blue">competitive</font> products or otherwise cover <font color="blue">commercially</font>     valuable products or processes</td>
    </tr>
    <tr>
      <td>In addition, because <font color="blue">patent <font color="blue"><font color="blue">application</font>s</font></font> in     the <font color="blue"><font color="blue">United States</font> </font>are maintained in secrecy for <font color="blue">eighteen months</font> after the     filing of the <font color="blue"><font color="blue">application</font>s</font>, and <font color="blue">publication</font> of <font color="blue">discoveries</font> in the scientific     or patent literature often lag behind actual <font color="blue">discoveries</font>, we cannot be sure     that the inventors of subject matter <font color="blue">covered by</font> our patents and patent     <font color="blue"><font color="blue">application</font>s</font>  were  the  first  to  invent or the first to <font color="blue">file patent</font>     <font color="blue"><font color="blue">application</font>s</font> for these <font color="blue">inventions</font></td>
    </tr>
    <tr>
      <td>In the event that a <font color="blue">third party</font> has also     filed  a  patent on a similar invention, we may have to <font color="blue">participate</font> in     <font color="blue">interference</font> <font color="blue">proceedings</font> declared by <font color="blue">the US Patent and Trademark Office </font>to     determine priority of invention, which could result in a loss of our patent     position</td>
    </tr>
    <tr>
      <td>Furthermore, we may not have identified all US and foreign     patents that pose a risk of <font color="blue">infringement</font></td>
    </tr>
    <tr>
      <td><font color="blue">Litigation </font>regarding patents and other <font color="blue"><font color="blue">proprietary</font> rights may</font> be expensive,     cause delays in <font color="blue">bringing products</font> to market and harm our ability to operate</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success will depend</font> in part on our ability to operate <font color="blue">without infringing</font>     the  <font color="blue">proprietary</font>  rights  of  <font color="blue">third parties</font> and <font color="blue">preventing others from</font>     infringing our patents</td>
    </tr>
    <tr>
      <td><font color="blue">Challenges </font><font color="blue">by pharmaceutical companies against</font> the     patents of <font color="blue">competitors</font> are common</td>
    </tr>
    <tr>
      <td>Legal standards relating to the validity     of patents covering pharmaceutical and biotechnological <font color="blue">inventions</font> and the     scope of claims made under these patents are still developing</td>
    </tr>
    <tr>
      <td>Third <font color="blue">parties may challenge</font>, in courts or     through patent office <font color="blue">proceedings</font>, or infringe upon, existing or future     patents</td>
    </tr>
    <tr>
      <td>In the event that a <font color="blue">third party</font> <font color="blue">challenges</font> a patent, a court or     patent office may invalidate the patent or                                           22     ______________________________________________________________________                                                  determine that the patent is not enforceable</td>
    </tr>
    <tr>
      <td><font color="blue">Proceedings </font>involving our     patents or <font color="blue">patent <font color="blue"><font color="blue">application</font>s</font></font> or those of <font color="blue">others could</font> result in adverse     <font color="blue">decisions about</font>:         •  the <font color="blue">patentability</font> of our <font color="blue">inventions</font>, products and <font color="blue">drug <font color="blue">candidates</font></font>; and/or       •   the enforceability, validity or scope of <font color="blue">protection offered by</font> our     patents</td>
    </tr>
    <tr>
      <td>The <font color="blue">manufacture</font>, use or sale of any of our products or <font color="blue">drug <font color="blue">candidates</font></font> may     infringe  on  the  patent  rights of others</td>
    </tr>
    <tr>
      <td>If we are unable to avoid     <font color="blue">infringement</font> of the <font color="blue">patent rights</font> of others, we may be required to seek a     license, defend an <font color="blue">infringement</font> action or challenge the validity of the     patents in court</td>
    </tr>
    <tr>
      <td>Patent <font color="blue">litigation</font> is costly and time consuming</td>
    </tr>
    <tr>
      <td>We may not     have <font color="blue">sufficient resources</font> to bring these actions to a <font color="blue">successful conclusion</font></td>
    </tr>
    <tr>
      <td>In addition, if we do not obtain a license, develop or obtain non-infringing     <font color="blue">technology</font>, fail to <font color="blue">successfully</font> defend an <font color="blue">infringement</font> action or have     <font color="blue">infringing patents</font> declared invalid, we may:         •  incur substantial <font color="blue">monetary damages</font>;       •  encounter <font color="blue">significant</font> delays in bringing our <font color="blue">drug <font color="blue">candidates</font></font> to market;     and/or       •  be <font color="blue">precluded from participating</font> in the <font color="blue">manufacture</font>, use or sale of our     products or <font color="blue">drug <font color="blue">candidates</font></font> or methods of treatment requiring licenses</td>
    </tr>
    <tr>
      <td>Our  business  has a substantial risk of <font color="blue">product <font color="blue">liability</font></font> claims, and     <font color="blue">insurance may</font> be expensive or unavailable</td>
    </tr>
    <tr>
      <td>Our  business <font color="blue">exposes us</font> to potential <font color="blue">product <font color="blue">liability</font></font> risks that are     inherent in the testing, <font color="blue">manufacturing</font> and marketing of <font color="blue">human therapeutic</font>     products</td>
    </tr>
    <tr>
      <td><font color="blue">Product  </font><font color="blue">liability</font> claims could result in the imposition of     substantial  <font color="blue">liability</font> on us, a recall of products, or a change in the     <font color="blue">indications</font> for which they may be used</td>
    </tr>
    <tr>
      <td>We currently have limited product     <font color="blue">liability</font> insurance</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that our <font color="blue">insurance will provide</font>     adequate  coverage against potential <font color="blue">liabilities</font></td>
    </tr>
    <tr>
      <td>Furthermore, product     <font color="blue">liability</font> insurance is <font color="blue">becoming increasingly expensive</font></td>
    </tr>
    <tr>
      <td>As a result, we may     not  be  able  to obtain <font color="blue">additional</font> insurance or obtain insurance at a     reasonable cost or in <font color="blue">sufficient amounts</font> to <font color="blue">protect against losses</font> that     could have a material adverse effect on us</td>
    </tr>
    <tr>
      <td>Delays in the conduct or <font color="blue">completion</font> of our <font color="blue">clinical trials</font>, the analysis of     the data from our <font color="blue">clinical trials</font>, or our <font color="blue">manufacturing</font> scale-up <font color="blue">activities</font>     may result in delays in our planned filings for <font color="blue">regulatory</font> approvals, and     may  <font color="blue">adversely</font>  affect  our  ability  to  <font color="blue">enter into</font> new <font color="blue">collaborative</font>     <font color="blue">arrangements</font></td>
    </tr>
    <tr>
      <td>We  cannot  <font color="blue">predict whether</font> we will encounter problems with any of our     completed,  ongoing  or planned <font color="blue">clinical studies</font> that will cause us or     <font color="blue">regulatory</font> <font color="blue">authorities</font> to delay or suspend our ongoing <font color="blue">clinical studies</font>,     delay or suspend planned <font color="blue">clinical studies</font>, or delay the analysis of data     from our completed or ongoing <font color="blue">clinical studies</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">also <font color="blue">cannot predict</font></font>     whether we <font color="blue">will encounter delays</font> or an <font color="blue">inability</font> to create <font color="blue">manufacturing</font>     processes for <font color="blue">drug <font color="blue">candidates</font></font> that allow us to produce <font color="blue">drug product</font> in large     enough  quantities  to be economical, otherwise known as <font color="blue">manufacturing</font>     scale-up</td>
    </tr>
    <tr>
      <td>If the results of our ongoing or planned <font color="blue">clinical studies</font> for our     <font color="blue">drug <font color="blue">candidates</font></font> are not available when we expect or if we encounter any     delay in the analysis of data from our <font color="blue">clinical studies</font> or if we encounter     delays in our ability to scale-up our <font color="blue">manufacturing</font> processes:         •   we may be unable to complete our <font color="blue">development</font> programs for exenatide LAR,     the treatment of obesity with pramlintide, or AC2592;       •   we may have to delay or terminate our planned filings for <font color="blue">regulatory</font>     approval;       •   we  may  not have the <font color="blue">financial resources</font> to <font color="blue">continue research</font> and     <font color="blue">development</font> of any of our <font color="blue">drug <font color="blue">candidates</font></font>; and       •   we may not be able to <font color="blue">enter into</font> <font color="blue">additional</font> <font color="blue">collaborative</font> <font color="blue">arrangements</font></td>
    </tr>
    <tr>
      <td>In addition, Lilly <font color="blue">may terminate</font> our <font color="blue">collaboration</font> for the <font color="blue">development</font> and     <font color="blue">commercialization</font> <font color="blue">of BYETTA </font>and sustained-release <font color="blue">formulation</font>s of exenatide     at any time on 60 days’ notice</td>
    </tr>
    <tr>
      <td>Moreover, if the FDA does not accept for     filing  an  NDA  for  a  sustained-release <font color="blue">formulation</font> of exenatide by     <font color="blue">December </font>31, 2007, Lilly will have the right to convert a portion of future     <font color="blue">milestone payments</font> that we may receive under our <font color="blue">collaboration</font> into shares     of our <font color="blue">common stock</font> at a <font color="blue"><font color="blue">conversion</font> price</font> equal to the <font color="blue">fair market value</font> of     our <font color="blue">common stock</font> at the time of any <font color="blue">such <font color="blue">conversion</font></font></td>
    </tr>
    <tr>
      <td>23     ______________________________________________________________________               Any of the <font color="blue">following could delay</font> the <font color="blue">completion</font> of our ongoing and planned     <font color="blue">clinical studies</font>:         •   <font color="blue">ongoing discussions with</font> the FDA or comparable foreign <font color="blue">authorities</font>     regarding the scope or design of our <font color="blue">clinical trials</font>;       •   delays in enrolling volunteers;       •   lower than anticipated retention rate of volunteers in a clinical trial;       •   negative results of <font color="blue">clinical studies</font>;       •   insufficient supply or deficient quality of <font color="blue">drug candidate</font> materials or     other materials <font color="blue">necessary</font> for the performance of <font color="blue">clinical trials</font>;       •   our <font color="blue">inability</font> to reach <font color="blue">agreement</font> with Lilly regarding the scope, design,     conduct  or costs of <font color="blue">clinical trials</font> <font color="blue">with respect</font> to sustained-release     <font color="blue">formulation</font>s of BYETTA; or       •   serious side effects experienced by study <font color="blue">participants</font> relating to a     <font color="blue">drug candidate</font></td>
    </tr>
    <tr>
      <td>We  may  be  unable  to obtain <font color="blue">regulatory</font> clearance to market our drug     <font color="blue">candidates</font> in the <font color="blue"><font color="blue">United States</font> </font>or foreign countries on a <font color="blue">timely basis</font>, or     at all</td>
    </tr>
    <tr>
      <td>Our <font color="blue">drug <font color="blue">candidates</font></font> are subject to extensive <font color="blue">government</font> <font color="blue">regulations</font> related     to <font color="blue">development</font>, <font color="blue">clinical trials</font>, <font color="blue">manufacturing</font> and <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>The     process  of  obtaining  FDA  and other <font color="blue">regulatory</font> approvals is costly,     time-consuming, uncertain and subject to <font color="blue">unanticipated</font> delays</td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Regulatory </font>    </font><font color="blue">authorities</font> may refuse to approve an <font color="blue">application</font> for approval of a drug     candidate  if they believe that applicable <font color="blue">regulatory</font> criteria are not     satisfied</td>
    </tr>
    <tr>
      <td><font color="blue">Regulatory </font><font color="blue">authorities</font> may also require <font color="blue">additional</font> testing for     safety and efficacy</td>
    </tr>
    <tr>
      <td>Moreover, if the FDA grants <font color="blue">regulatory</font> approval of a     product, the <font color="blue">approval may</font> be limited to specific <font color="blue">indications</font> or limited with     respect to its <font color="blue">distribution</font>, and expanded or <font color="blue">additional</font> <font color="blue">indications</font> for     <font color="blue">approved drugs may</font> not be approved, which could limit our revenues</td>
    </tr>
    <tr>
      <td><font color="blue">Foreign     </font><font color="blue">regulatory</font> <font color="blue">authorities</font> may apply similar <font color="blue">limitations</font> or may refuse to grant     any approval</td>
    </tr>
    <tr>
      <td>The <font color="blue">data collected from</font> our <font color="blue">clinical trials</font> may not be sufficient to support     initial  approval  of  our  drug  <font color="blue">candidates</font> or <font color="blue">additional</font> or expanded     <font color="blue">indications</font> by the FDA or any foreign <font color="blue">regulatory</font> <font color="blue">authorities</font></td>
    </tr>
    <tr>
      <td>Bio<font color="blue">technology</font>     stock  prices  have  declined <font color="blue">significant</font>ly in <font color="blue">certain instances</font> where     companies have failed to <font color="blue">meet expectations <font color="blue">with respect</font></font> to FDA approval or     the  timing  for FDA approval</td>
    </tr>
    <tr>
      <td>If the FDA’s response is delayed or not     favorable for any of our <font color="blue">drug <font color="blue">candidates</font></font>, our <font color="blue">stock price could decline</font>     <font color="blue">significant</font>ly</td>
    </tr>
    <tr>
      <td>Moreover, <font color="blue"><font color="blue">manufacturing</font> <font color="blue">facilities</font></font> operated by the third-party <font color="blue"><font color="blue">manufacture</font>rs</font>     with whom we <font color="blue">may contract</font> to <font color="blue">manufacture</font> our unapproved <font color="blue">drug <font color="blue">candidates</font></font> may     not pass an FDA or other <font color="blue">regulatory</font> authority preapproval inspection</td>
    </tr>
    <tr>
      <td>Any     failure or delay in obtaining these <font color="blue">approvals could prohibit</font> or <font color="blue">delay us</font> or     any of our business <font color="blue">partners from marketing</font> these <font color="blue">drug <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Consequently, even if we believe that preclinical and <font color="blue">clinical data</font> are     sufficient to support <font color="blue">regulatory</font> approval for our <font color="blue">drug <font color="blue">candidates</font></font>, the FDA     and foreign <font color="blue">regulatory</font> <font color="blue">authorities</font> may not ultimately approve our drug     <font color="blue">candidates</font> for commercial sale in any <font color="blue">jurisdiction</font></td>
    </tr>
    <tr>
      <td>If our <font color="blue">drug <font color="blue">candidates</font></font>     are not approved, our ability to <font color="blue">generate revenues</font> may be limited and our     business will be <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>Our  ability  to  <font color="blue">enter into</font> and maintain third-party relationships is     important to our successful <font color="blue">development</font> and <font color="blue">commercialization</font> of BYETTA,     SYMLIN, and our other <font color="blue">drug <font color="blue">candidates</font></font> and to our <font color="blue">potential profitability</font></td>
    </tr>
    <tr>
      <td>To market any of our products in the <font color="blue"><font color="blue">United States</font> </font>or elsewhere, we must     develop <font color="blue">internally</font> or obtain access to sales and marketing forces with     technical expertise and with supporting <font color="blue">distribution</font> <font color="blue">capability</font> in the     relevant  geographic  territory</td>
    </tr>
    <tr>
      <td>With respect to sales, marketing and     <font color="blue">distribution</font> outside <font color="blue">the <font color="blue">United States</font></font>, we will be <font color="blue">substantially</font> <font color="blue">dependent</font>     on  Lilly  for  <font color="blue">activities</font>  relating  to  BYETTA and sustained-release     <font color="blue">formulation</font>s of BYETTA, including exenatide LAR We believe that we will     likely need to <font color="blue">enter into</font> marketing and <font color="blue">distribution</font> <font color="blue">arrangements</font> with third     parties for, or find a <font color="blue">corporate partner</font> who can <font color="blue">provide support</font> for, the     <font color="blue">development</font> and <font color="blue">commercialization</font> of SYMLIN or our other <font color="blue">drug <font color="blue">candidates</font></font>     outside <font color="blue">the <font color="blue">United States</font></font></td>
    </tr>
    <tr>
      <td>We may also <font color="blue">enter into</font> <font color="blue">arrangements</font> with third     parties  for  the <font color="blue">commercialization</font> of SYMLIN or any of our other drug     <font color="blue">candidates</font> within <font color="blue">the <font color="blue">United States</font></font></td>
    </tr>
    <tr>
      <td>With  respect  to  BYETTA  and,  if  approved, exenatide LAR, Lilly is     co-promoting within <font color="blue">the <font color="blue">United States</font></font></td>
    </tr>
    <tr>
      <td>If Lilly ceased <font color="blue">commercializing</font>     BYETTA or, if approved, exenatide LAR, for any reason, we <font color="blue">would likely</font> need     to either <font color="blue">enter into</font> a marketing and <font color="blue">distribution</font> arrangement with a third     party for those products or <font color="blue">significant</font>ly increase our <font color="blue">internal sales</font> and     <font color="blue">commercialization</font> infrastructure</td>
    </tr>
    <tr>
      <td>We may not be able to <font color="blue">enter into</font> marketing and <font color="blue">distribution</font> <font color="blue">arrangements</font> or     find a <font color="blue">corporate partner</font> for SYMLIN or our other <font color="blue">drug <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>If we are     not able to <font color="blue">enter into</font> a marketing or <font color="blue">distribution</font> arrangement or find a     <font color="blue">corporate partner</font> who can <font color="blue">provide support</font> for <font color="blue">commercialization</font> of our drug     <font color="blue">candidates</font> as we deem <font color="blue">necessary</font>, we may not be able to <font color="blue">successfully</font> perform     these marketing or <font color="blue">distribution</font> <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>Moreover, any new marketer or     <font color="blue">distributor</font> or <font color="blue">corporate partner</font> for our <font color="blue">drug <font color="blue">candidates</font></font>, including Lilly,     with  whom  we choose to <font color="blue">contract may</font> not <font color="blue">establish adequate sales</font> and     <font color="blue">distribution</font> capabilities or gain market <font color="blue">acceptance</font> for our products, if     any</td>
    </tr>
    <tr>
      <td>24     ______________________________________________________________________                                                  We have a <font color="blue">significant</font> amount of <font color="blue">indebtedness</font></td>
    </tr>
    <tr>
      <td>We may not be able to make     <font color="blue">payments on</font> our <font color="blue">indebtedness</font>, and we may incur <font color="blue">additional</font> <font color="blue">indebtedness</font> in     the future, which could <font color="blue">adversely</font> affect our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We  have  substantial  <font color="blue">indebtedness</font> outstanding and have the potential     <font color="blue">borrowing capacity under</font> our <font color="blue">collaboration</font> with Lilly of up to dlra110 million</td>
    </tr>
    <tr>
      <td><font color="blue">In June and July </font>2003, we issued dlra175 million of 2dtta25prca <font color="blue">convertible senior</font>     notes due 2008</td>
    </tr>
    <tr>
      <td>Our ability to make <font color="blue">payments on</font> our debt, including     the notes, <font color="blue">will depend on</font> our future operating performance and ability to     <font color="blue">generate cash</font> and <font color="blue">may also depend on</font> our ability to obtain <font color="blue">additional</font> debt     or <font color="blue">equity financing</font></td>
    </tr>
    <tr>
      <td>During each of the <font color="blue">last five years</font>, our operating cash     flows were negative and insufficient to cover our fixed charges</td>
    </tr>
    <tr>
      <td>We may need     to use our cash to <font color="blue">pay principal</font> and <font color="blue">interest on</font> our debt, thereby reducing     the funds available to fund our research and <font color="blue">development</font> programs, strategic     <font color="blue">initiatives</font>  and working capital <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>Our ability to generate     sufficient operating <font color="blue">cash flow</font> to service our <font color="blue">indebtedness</font>, including the     notes, and fund our operating <font color="blue">requirements</font> <font color="blue">will depend on</font> our ability, alone     or  <font color="blue">with others</font>, to <font color="blue">successfully</font> develop, <font color="blue">manufacture</font>, obtain required     <font color="blue">regulatory</font> approvals for and market our <font color="blue">drug <font color="blue">candidates</font></font>, as well as other     factors, including general economic, financial, <font color="blue">competitive</font>, legislative and     <font color="blue">regulatory</font>  <font color="blue">conditions</font>, some of which are beyond our control</td>
    </tr>
    <tr>
      <td>Our debt     <font color="blue">service obligations increase</font> our <font color="blue">vulnerabilities</font> to <font color="blue">competitive</font> pressures,     because many of our <font color="blue">competitors</font> are <font color="blue">less leveraged than</font> we are</td>
    </tr>
    <tr>
      <td>If we are     unable  to  generate  sufficient  operating  cash  flow to service our     <font color="blue">indebtedness</font> and fund our operating <font color="blue">requirements</font>, we may be forced to reduce     our <font color="blue">development</font> programs, sell assets or seek <font color="blue">additional</font> debt or equity     financing, which may not be available to us on satisfactory terms or at all</td>
    </tr>
    <tr>
      <td>Our  level  of <font color="blue">indebtedness</font> may make us more vulnerable to economic or     <font color="blue">industry downturns</font></td>
    </tr>
    <tr>
      <td>If we incur new <font color="blue">indebtedness</font>, the risks relating to our     business and our ability to service our <font color="blue">indebtedness</font> will intensify</td>
    </tr>
    <tr>
      <td>We may be required to redeem our <font color="blue">convertible senior</font> notes upon a designated     event</td>
    </tr>
    <tr>
      <td><font color="blue">Holders  </font>of  our 2dtta25prca <font color="blue">convertible senior</font> notes due 2008 and our 2dtta50prca     convertible  senior notes due 2011 may require us to redeem all or any     portion of their notes upon the occurrence of <font color="blue">certain <font color="blue">designated event</font>s</font>     which <font color="blue">generally</font> involve a change in control of our company</td>
    </tr>
    <tr>
      <td>We may not have     <font color="blue">sufficient cash funds</font> to redeem the notes upon a <font color="blue">designated event</font></td>
    </tr>
    <tr>
      <td>We may     elect, subject to certain <font color="blue">conditions</font>, to pay the <font color="blue"><font color="blue">redemption</font> price</font> in our     <font color="blue">common stock</font> or a <font color="blue">combination</font> of cash and our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>We may be unable     to satisfy the requisite <font color="blue">conditions</font> to <font color="blue">enable us</font> to pay some or all of the     <font color="blue">redemption</font>  price in our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>In addition, although there are     currently no <font color="blue">restrictions</font> on our ability to pay the <font color="blue"><font color="blue">redemption</font> price</font> under     our existing debt <font color="blue">agreement</font>s, future debt <font color="blue">agreement</font>s may prohibit us from     repaying the <font color="blue"><font color="blue">redemption</font> price</font> in <font color="blue">either cash</font> or <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>If we are     <font color="blue">prohibited from redeeming</font> the notes, we <font color="blue">could seek consent from</font> our lenders     to redeem the notes</td>
    </tr>
    <tr>
      <td>If we were unable to obtain a consent or     refinance, we would be <font color="blue">prohibited from redeeming</font> the notes</td>
    </tr>
    <tr>
      <td>If we were     unable to redeem the notes upon a <font color="blue">designated event</font>, it would result in an     event of <font color="blue">default under</font> the <font color="blue">indentures governing</font> the notes</td>
    </tr>
    <tr>
      <td>An event of     <font color="blue">default under</font> the indentures could result in a <font color="blue">further event</font> of default     under  our  other then-existing debt</td>
    </tr>
    <tr>
      <td>In addition, the occurrence of a     <font color="blue">designated event</font> may be an event of <font color="blue">default under</font> our other debt</td>
    </tr>
    <tr>
      <td>If our research and <font color="blue">development</font> programs fail to result in <font color="blue">additional</font> drug     <font color="blue">candidates</font>, our ability to <font color="blue">generate revenue will</font> be <font color="blue">substantially</font> limited</td>
    </tr>
    <tr>
      <td>Our research and <font color="blue">development</font> programs for <font color="blue">drug <font color="blue">candidates</font></font> are at an early     stage and will require <font color="blue">significant</font> research, <font color="blue">development</font>, preclinical and     clinical testing, <font color="blue">manufacturing</font> scale-up <font color="blue">activities</font>, <font color="blue">regulatory</font> approval     and/or commitments of resources before <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict</font>     whether our <font color="blue">research will lead</font> to the <font color="blue">discovery</font> of any <font color="blue">additional</font> drug     <font color="blue">candidates</font> that could <font color="blue">generate revenues</font> for us</td>
    </tr>
    <tr>
      <td>Our <font color="blue">future success depends on</font> our ability to retain our <font color="blue">chief executive</font>     officer  and  other <font color="blue">key executives</font> and to attract, retain and motivate     <font color="blue">qualified personnel</font></td>
    </tr>
    <tr>
      <td>We  are  highly <font color="blue">dependent</font> on Ginger L Graham, our President and Chief     Executive Officer, and the other <font color="blue">principal members</font> of our executive and     <font color="blue">scientific teams</font></td>
    </tr>
    <tr>
      <td>The loss of the services of any of these <font color="blue">persons might</font>     impede the <font color="blue">achievement</font> of our research, <font color="blue">development</font> and <font color="blue">commercialization</font>     <font color="blue">objectives</font></td>
    </tr>
    <tr>
      <td><font color="blue">Recruiting </font>and retaining qualified sales, marketing, scientific     and other personnel and <font color="blue">consultants will also</font> be critical to our success</td>
    </tr>
    <tr>
      <td>We     may not be able to attract and retain these personnel and <font color="blue">consultants on</font>     acceptable <font color="blue">terms given</font> the <font color="blue">competition between numerous pharmaceutical</font> and     bio<font color="blue">technology</font> companies</td>
    </tr>
    <tr>
      <td>We do not maintain “key person” <font color="blue">insurance on</font> any of     our employees</td>
    </tr>
    <tr>
      <td>We may be unable to <font color="blue">adequately prevent disclosure</font> of <font color="blue">trade secrets</font> and other     <font color="blue">proprietary</font> information</td>
    </tr>
    <tr>
      <td>In order to protect our <font color="blue">proprietary</font> <font color="blue">technology</font> and processes, we rely in     part on <font color="blue">confidential</font>ity <font color="blue">agreement</font>s with our <font color="blue">corporate partner</font>s, employees,     consultants, outside scientific collaborators and <font color="blue">sponsored researchers</font> and     other advisors</td>
    </tr>
    <tr>
      <td>These <font color="blue">agreement</font>s may not <font color="blue">effective</font>ly prevent disclosure of     <font color="blue">confidential</font> information and may not provide an <font color="blue">adequate remedy</font> in the event     of <font color="blue">unauthorized disclosure</font> of <font color="blue">confidential</font> information</td>
    </tr>
    <tr>
      <td>In addition, others     may in<font color="blue">dependent</font>ly discover <font color="blue">trade secrets</font> and <font color="blue">proprietary</font> information</td>
    </tr>
    <tr>
      <td>25     ______________________________________________________________________                                                  Costly and time-consuming <font color="blue">litigation</font> could be <font color="blue">necessary</font> to enforce and     determine the scope of our <font color="blue">proprietary</font> rights, and failure to obtain or     maintain trade secret protection could <font color="blue">adversely</font> affect our <font color="blue">competitive</font>     business position</td>
    </tr>
    <tr>
      <td>Our <font color="blue">activities</font> involve the use of <font color="blue">hazardous</font> materials, which subject us to     regulation, related costs and delays and potential <font color="blue">liabilities</font></td>
    </tr>
    <tr>
      <td>Our  research and <font color="blue">development</font> involves the <font color="blue">controlled use</font> of <font color="blue">hazardous</font>     materials, chemicals and <font color="blue">various radioactive compounds</font></td>
    </tr>
    <tr>
      <td>Although we believe     that our <font color="blue">safety procedures</font> for handling and disposing of these materials     <font color="blue">comply with</font> the <font color="blue">standards prescribed by</font> state and federal <font color="blue">regulations</font>, the     risk of <font color="blue"><font color="blue">accident</font>al contamination</font> or <font color="blue">injury from</font> these <font color="blue">materials cannot</font> be     eliminated</td>
    </tr>
    <tr>
      <td>If an <font color="blue">accident</font> occurs, we could be held liable for resulting     damages,  which  could be substantial</td>
    </tr>
    <tr>
      <td>We are also subject to numerous     environmental, health and <font color="blue">workplace safety laws</font> and <font color="blue">regulations</font>, including     those governing laboratory procedures, exposure to blood-borne pathogens and     the handling of bio<font color="blue">hazardous</font> materials</td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font>federal, state and local     laws and <font color="blue">regulations</font> affecting our <font color="blue">operations</font> may be adopted in the future</td>
    </tr>
    <tr>
      <td>We may incur substantial costs to <font color="blue">comply with</font>, and substantial fines or     penalties if we violate, any of these laws or <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>We  have implemented anti-takeover provisions that <font color="blue">could discourage</font> or     prevent an <font color="blue">acquisition</font> of our company, even if the <font color="blue">acquisition</font> would be     <font color="blue">beneficial</font> to our <font color="blue">stockholders</font>, and as a result our <font color="blue"><font color="blue">management</font> may become</font>     entrenched and hard to replace</td>
    </tr>
    <tr>
      <td><font color="blue">Provisions </font>in our <font color="blue">certificate</font> of <font color="blue">incorporation</font> and bylaws could make it more     <font color="blue">difficult</font> for a <font color="blue">third party</font> to acquire us, even if doing so <font color="blue">would benefit</font>     our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>These provisions include:         •   allowing our board of <font color="blue">directors</font> to elect a director to fill a vacancy     created by the expansion of the board of <font color="blue">directors</font>;       •   allowing our board of <font color="blue">directors</font> to issue, without stockholder approval,     up to 5dtta5 million shares of <font color="blue">preferred stock with terms set by</font> the board of     <font color="blue">directors</font>;       •   limiting the ability of holders of our outstanding <font color="blue">common stock</font> to call     a <font color="blue">special meeting</font> of our <font color="blue">stockholders</font>; and       •   preventing <font color="blue">stockholders</font> from taking actions by written consent and     requiring  all  stockholder  actions  to  be taken at a meeting of our     <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>Each of these provisions, as well as selected provisions <font color="blue">of <font color="blue">Delaware </font></font>law,     <font color="blue">could discourage</font> potential takeover attempts, could <font color="blue">adversely</font> affect the     <font color="blue">trading price</font> of our securities and could cause our <font color="blue">management</font> to become     entrenched and hard to replace</td>
    </tr>
    <tr>
      <td>In addition to provisions in our charter     <font color="blue">documents</font> and under <font color="blue">Delaware </font>law, an <font color="blue">acquisition</font> of our <font color="blue">company could</font> be     made more <font color="blue">difficult</font> by our employee benefits plans and our employee change     in control plan, under which, in <font color="blue">connection with</font> a change in control, stock     options held by our <font color="blue">employees may become vested</font> and our <font color="blue">executive officers</font>     may receive <font color="blue">severance benefits</font></td>
    </tr>
    <tr>
      <td>We also have implemented a stockholder     rights plan, also called a poison pill, which could make it uneconomical for     a <font color="blue">third party</font> to acquire us on a <font color="blue">hostile basis</font></td>
    </tr>
    <tr>
      <td>Our  executive  officers,  <font color="blue">directors</font>  and  major  <font color="blue">stockholders</font> control     <font color="blue">approximately</font> 46prca of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td><font color="blue">As of <font color="blue">December </font></font>31, 2005, <font color="blue">executive officers</font>, <font color="blue">directors</font> and holders of 5prca or     more of our outstanding <font color="blue">common stock</font>, in the aggregate, owned or controlled     <font color="blue">approximately</font>  46prca of our outstanding <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>As a result, these     <font color="blue">stockholders</font> are able to influence all matters requiring approval by our     <font color="blue">stockholders</font>,  including the election of <font color="blue">directors</font> and the approval of     <font color="blue">corporate <font color="blue">transactions</font></font></td>
    </tr>
    <tr>
      <td>This <font color="blue">concentration</font> of <font color="blue">ownership may also delay</font>,     deter  or prevent a change in control of our company and may make some     <font color="blue">transactions</font> more <font color="blue">difficult</font> or impossible to complete without the support of     these <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td><font color="blue">Substantial  </font>future  sales  of  our <font color="blue">common stock</font> by us or our existing     <font color="blue">stockholders</font> or the <font color="blue">conversion</font> of our <font color="blue">convertible senior</font> notes to common     <font color="blue">stock could</font> cause the <font color="blue">trading price</font> of our <font color="blue">common stock</font> to fall</td>
    </tr>
    <tr>
      <td>Sales by existing <font color="blue">stockholders</font> of a large number of shares of our common     stock in the <font color="blue">public market</font> or the <font color="blue">perception</font> that <font color="blue">additional</font> sales could     occur could cause the <font color="blue">trading price</font> of our <font color="blue">common stock</font> to drop</td>
    </tr>
    <tr>
      <td>Likewise,     the issuance of shares of <font color="blue">common stock</font> upon <font color="blue">conversion</font> of our convertible     notes or <font color="blue">redemption</font> of our convertible notes upon a <font color="blue">designated event</font>, or     upon  <font color="blue">additional</font>  convertible debt or <font color="blue">equity financing</font>s or other share     <font color="blue">issuances by us</font>, including <font color="blue">shares issued</font> in <font color="blue">connection with</font> potential future     <font color="blue">strategic alliances</font> and the uncertain number of <font color="blue">additional</font> shares that we     may be required to <font color="blue">issue under</font> our <font color="blue">agreement</font>s with Lilly, could <font color="blue">adversely</font>     affect the <font color="blue">trading price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Our convertible notes are     <font color="blue">currently convertible into</font> a total of up to <font color="blue">approximately</font> 11dtta2 million     shares</td>
    </tr>
    <tr>
      <td>In addition, the existence of these notes <font color="blue">may encourage</font> short     selling of our <font color="blue">common stock</font> by market <font color="blue">participants</font></td>
    </tr>
    <tr>
      <td>26     ______________________________________________________________________                  <font color="blue">Significant </font><font color="blue">volatility</font> in the <font color="blue">market price</font> for our <font color="blue">common stock</font> could expose     us to <font color="blue">litigation</font> risk</td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font>s for securities of <font color="blue">biopharmaceutical</font> and bio<font color="blue">technology</font>     companies,  including  our <font color="blue">common stock</font>, have <font color="blue">historically been highly</font>     volatile, and the <font color="blue">market from</font> time to time has experienced <font color="blue">significant</font> price     and <font color="blue">volume <font color="blue">fluctuations</font></font> that are unrelated to the operating performance of     these <font color="blue">biopharmaceutical</font> and bio<font color="blue">technology</font> companies</td>
    </tr>
    <tr>
      <td><font color="blue">Since January </font>1, 2004,     the high and <font color="blue">low sales price</font> of our <font color="blue">common stock</font> varied <font color="blue">significant</font>ly, as     shown in the <font color="blue">following table</font>:                                                                                            High                                                                                  Low                                                 Year ending <font color="blue">December </font>31, 2006                 <font color="blue">First Quarter </font>through March 1, 2006         $                                                                        45dtta79         $                                                                        35dtta58                     Year ended <font color="blue">December </font>31, 2005                 Fourth Quarter         $                                                                        42dtta36         $                                                                        32dtta63         <font color="blue">Third Quarter         </font>35dtta47         18dtta50         <font color="blue">Second Quarter         </font>21dtta73         14dtta50         <font color="blue">First Quarter </font>        24dtta95         17dtta15                     Year ended <font color="blue">December </font>31, 2004                 Fourth Quarter         $                                                                        24dtta01         $                                                                        18dtta80         <font color="blue">Third Quarter         </font>23dtta25         16dtta48         <font color="blue">Second Quarter         </font>26dtta80         19dtta69         <font color="blue">First Quarter </font>        25dtta63         18dtta49           Given   the   <font color="blue">uncertainty</font>   of  our  future  funding,  the  successful     <font color="blue">commercialization</font> of <font color="blue">BYETTA and SYMLIN </font>and the <font color="blue">regulatory</font> approval of our     other <font color="blue">drug <font color="blue">candidates</font></font>, we <font color="blue">may continue</font> to experience <font color="blue">volatility</font> in our stock     price for the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>In addition, the <font color="blue">following factors may</font>     <font color="blue">significant</font>ly affect the <font color="blue">market price</font> of our <font color="blue">common stock</font>:         •  our financial results;       •  <font color="blue">clinical study</font> results;       •   de<font color="blue">termination</font>s  by <font color="blue">regulatory</font> <font color="blue">authorities</font> <font color="blue">with respect</font> to our drug     <font color="blue">candidates</font>;       •  <font color="blue">development</font>s in our <font color="blue">relationships with current</font> or future <font color="blue">collaborative</font>     partners;       •  our ability to <font color="blue">successfully</font> implement our <font color="blue">commercialization</font> strategies;       •  <font color="blue">fluctuations</font> in our operating results;       •  <font color="blue">development</font>s in our relationships with third-party <font color="blue"><font color="blue">manufacture</font>rs</font> of our     products and other parties who <font color="blue">provide services</font> to us;       •  public concern as to the safety of drugs that we are developing;       •  <font color="blue">technological innovations</font> or new commercial <font color="blue">therapeutic products</font> by us or     our <font color="blue">competitors</font>;       •  <font color="blue">development</font>s in patent or other <font color="blue">proprietary</font> rights; and       •  <font color="blue"><font color="blue">government</font>al</font> policy or regulation, including <font color="blue">with respect</font> to pricing and     <font color="blue">reimbursement</font></td>
    </tr>
    <tr>
      <td>Broad market and industry factors also may materially <font color="blue">adversely</font> affect the     market  price  of our <font color="blue">common stock</font>, regardless of our actual operating     performance</td>
    </tr>
    <tr>
      <td>Periods of <font color="blue">volatility</font> in the <font color="blue">market price</font> of our <font color="blue">common stock</font>     expose us to securities class-action <font color="blue">litigation</font>, and we <font color="blue">may continue</font> to be     the target of such <font color="blue">litigation</font> as a result of <font color="blue">market price</font> <font color="blue">volatility</font> in the     future</td>
    </tr>
    <tr>
      <td>We  are  exposed  to <font color="blue">potential risks from recent legislation</font> requiring     companies to <font color="blue">evaluate <font color="blue"><font color="blue">internal controls</font> <font color="blue">over financial</font></font></font> reporting</td>
    </tr>
    <tr>
      <td>The Sarbanes-Oxley Act requires that we report <font color="blue">annually on</font> the <font color="blue">effective</font>ness     of our <font color="blue"><font color="blue">internal controls</font> <font color="blue">over financial</font></font> reporting</td>
    </tr>
    <tr>
      <td>Among other things, we     must perform systems and processes <font color="blue">evaluation</font> and testing</td>
    </tr>
    <tr>
      <td>We must also     conduct an <font color="blue">assessment</font> of our <font color="blue">internal controls</font> to allow <font color="blue">management</font> to report     on, and our in<font color="blue">dependent</font> registered public <font color="blue">accounting</font> firm to attest to, our     <font color="blue">assessment</font> of our <font color="blue"><font color="blue">internal controls</font> <font color="blue">over financial</font></font> reporting, as required by     Section 404 of the Sarbanes-Oxley Act</td>
    </tr>
    <tr>
      <td>These <font color="blue">requirements</font> became <font color="blue">effective</font>     for the first time for our <font color="blue">fiscal year</font> ended <font color="blue">December </font>31, 2004, and neither     we nor our in<font color="blue">dependent</font> registered public <font color="blue">accounting</font> firm had <font color="blue">previously</font>     performed an <font color="blue">evaluation</font> of our <font color="blue"><font color="blue">internal controls</font> <font color="blue">over financial</font></font> reporting     under  these  new rules</td>
    </tr>
    <tr>
      <td>In <font color="blue">connection with</font> our Section 404 compliance     efforts, we have incurred or expended, and expect to continue to incur or     expend, substantial <font color="blue">accounting</font> and other expenses and <font color="blue">significant</font> <font color="blue">management</font>     time and resources</td>
    </tr>
    <tr>
      <td>We have implemented certain remediation <font color="blue">activities</font>     resulting from our <font color="blue">ongoing <font color="blue">assessment</font></font> of <font color="blue"><font color="blue">internal controls</font> <font color="blue">over financial</font></font>     reporting</td>
    </tr>
    <tr>
      <td>Our  future  <font color="blue">assessment</font>,  or the future <font color="blue">assessment</font>s by our     in<font color="blue">dependent</font>  registered  public  <font color="blue">accounting</font>  firm, may reveal material     <font color="blue">weaknesses</font> in our <font color="blue">internal controls</font></td>
    </tr>
    <tr>
      <td>If material <font color="blue">weaknesses</font> are identified     in the future we would be required to conclude that our <font color="blue">internal controls</font>     <font color="blue">over financial</font> reporting are                                           27     ______________________________________________________________________                                                  in<font color="blue">effective</font> and we could be subject to sanctions or <font color="blue">investigations</font> by the     SEC, the NASDAQ National Market or other <font color="blue">regulatory</font> <font color="blue">authorities</font>, which would     require <font color="blue">additional</font> financial and <font color="blue">management</font> resources and could <font color="blue">adversely</font>     affect the <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
  </tbody>
</table>